Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
294 articles
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
A landmark Lancet review reveals GLP-1 receptor agonists protect the heart, kidneys, liver, and brain — reshaping how we think about metabolic medicine.
New research reveals how fatty liver disease reshapes the tumor microenvironment, potentially accelerating cancer metastasis.
A 5-year study finds bariatric surgery offers meaningful but attenuated weight loss in PWS kids versus lifestyle intervention alone.
A large real-world study finds post-transplant diabetes requiring insulin marks a high-risk metabolic phenotype with far worse graft and patient outcomes.
A new framework redefines age-related insulin resistance as a systemic collapse of metabolic resilience spanning muscle, fat, brain, and more.
A molecular-level deep dive into AGE formation kinetics, RAGE isoforms, downstream transcriptional networks, and evidence-based interventions — for those who want the full mechanistic picture.
Go beyond the basics and explore the biochemical mechanisms behind glycation — from the Maillard reaction cascade to RAGE signaling and tissue cross-linking — to understand why AGEs are central to aging and metabolic disease.
Discover how sugar molecules quietly damage your proteins and cells over time — and what you can do to slow down this sneaky aging process.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
A new review links feline age-related obesity to SASP-driven chronic inflammation, offering translational insights for human metabolic disease.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
